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Abstract 
 
Tuberculosis remains the biggest infectious killer in India and worldwide, and it has recently 
regained substantial international attention with its come-back in drug resistant forms. The 
environment, the disease and the societal response to it are changing and with it challenges and 
opportunities to control the disease. Innovation in a variety of areas such as improved diagnostic 
tests, drugs, delivery mechanisms, service processes, institutions and treatment regimes is 
needed in order to be able to respond to the changing public health challenge. 
This paper reviews theoretical approaches to innovation of direct relevance to the case and 
examines what theoretical framework is useful to look at the problem of innovation in public 
health in India. Such an analysis can reveal drivers and barriers of change within the context of 
the Indian health system in a comprehensive, problem-oriented way and is thus able to add to 
existing research done on TB. 
However, given that TB control is a public health challenge, concerned with problems of 
delivery and implementation, the concept of innovation has to go beyond technological 
innovation and the private sector. Therefore it is argued that the case can simultaneously 
contribute to innovation theory in order to better understand what change processes and 
innovation for concrete public health challenges in a country such as India mean.  
After a short description of recent changes in TB control based on fieldwork in India the paper 
proceeds with an examination of existing frameworks on healthcare innovation upon their 
usefulness for such a case. The paper concludes with a proposal for a theoretical framework and 
areas for further empirical fieldwork. 
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1. Introduction 
 
Tuberculosis (TB) is an infectious disease which can be transmitted through air and requires a 
very long and complicated treatment. Although there have been effective drugs around for 50 
years there has not been enough serious effort to control the disease. Today, TB remains the first 
among the world’s infectious killers, with more people dying from it than ever before. The TB 
crisis is worsening worldwide with increasing multi-drug resistant forms1, so much so that 
experts are speaking of a timebomb that is about to explode and for which we are not prepared 
(Reichman & Hopkins, 2002).  
There has been increasing international attention to the threat of multi-drug resistant (MDR-TB) 
and extreme multi-drug resistant Tuberculosis (XDR-TB) fuelled by the outbreak of XDR-TB in 
South Africa in 2006 which was widely published (Neel, Gandhi, et al., 2006). It is feared that in 
a country like India with the highest existing burden of TB in the world the potential effect of 
MDR-TB on ongoing control efforts might be devastating, eliminating the successes achieved so 
far (Interview with public health consultant, international PPP, Pune, 29.1.2008). Next to 
increasing drug resistance the ongoing TB control efforts are characterized by new challenges 
such as co-infection with HIV, changing migration patterns, urbanization and weakening public 
health systems. In the same time new opportunities are emerging such as increased international 
political attention to TB, new financial resources, new international actors and advances in 
technologies and medicine.  
The ecology of human diseases and the use of specialised knowledge to influence the former are 
today both subject to rapid changes. More and more actors are involved in the production, access 
and application of divers forms of health-related knowledge and thus there is a greater potential 
for rapid responses but also a risk of greater uncertainties with regard to the formulation of a 
coordinated response. It is thus central to reflect upon forms of institutions, governance and 
design of interventions to deal with dynamic health challenges (Bloom et al., 2007) such as 
Tuberculosis. 
                                                 
1
 Multi-drug resistant Tuberculosis (MDR-TB) is defined as resistance to at least Rifampicin and Isoniazid, two of 
the most important standard anti-TB drugs. It develops due to infection with a resistant strain or due to poor 
treatment with inadequate drugs, insufficient drugs, selective, unstructured drug intake, poor drug quality or 
irregular drug supply (Central TB Division, India, 2007). XDR-TB, or Extensive Drug Resistant TB (also referred to 
as Extreme Drug Resistance) is MDR-TB that is also resistant to three or more of the six classes of second-line 
drugs (WHO, http://www.who.int/tb/challenges/xdr/en/index.html, accessed 20.10.2008). 
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In international policy arenas it has been argued that flexibility and innovation in public health 
systems are needed in order to react to this kind of changing challenges and opportunities2 
(EASAC, 2006; Eurosurveillance, 2005; WHO, 2003b; Alan, 2003). For the case of TB and 
MDR-TB in India innovation in a variety of areas such as improved diagnostic tests, drugs, 
delivery mechanisms, service processes, institutions, understandings and treatment regimes is 
needed in order to be able to respond to the changing public health challenge. 
 
This paper will review theoretical approaches to innovation of direct relevance to the case of TB 
control3 and examine what theoretical framework is useful to look at the problem of innovation 
in public health in India. 
What has a perspective on innovation processes to offer beyond what is already known from the 
existing literature? The TB control efforts in India have been researched and analyzed from 
various disciplinary perspectives (see Porter & Grange, 1999 for an overview). Epidemiological 
studies estimate the changing burden of the disease, clinical and biomedical research is trying to 
improve drug regimens, products and processes for diagnosis and treatment. Research from an 
anthropological or sociological perspective analyzes among others the factors influencing 
adherence to treatment, different understandings of TB within communities, gender aspects, 
reasons for delays in diagnosis or quality of services, importance of poverty and social justice, 
thus trying to improve program performance (Narayanan et al., 2003; Porter & Grange, 1999; 
Murthy et al., 2001; Rangan, Ambe et al., 2003; Rangan, Gupte et al., 2003; Shina et al., 2004). 
This research is often subsumed under the expression operational research. In general, social 
sciences are suited to describe the range of diverse factors characterizing an infectious disease 
and a society’s response towards it (Lienhardt, Ogden & Sow, 2003; Walt, 1999). There is a 
complexity of structural factors strongly related to poverty that promote or retard the emergence 
or re-emergence of infectious disease for which Paul Farmer (1998) argued. Literature on the 
politics of TB control (Walt, 1999; Ogden, Walt & Lush, 2003; Porter & Kiehlmann, 2003) 
                                                 
2
 The flexibility in reaction that is needed is concerned with preparation of response and innovative capacity in a 
variety of areas such as rapid identification and surveillance, public health infrastructure, vaccines, diagnostics and 
therapeutics, training and manpower in clinical sciences and coordination of science agendas (Eurosurveillance, 
2005). Besides large investment in different forms of R&D (EASAC, 2006) the challenges are to develop new 
public health solutions that are affordable, acceptable and applicable to local setting (WHO, 2003).  
3
 Evidence has been collected during exploratory fieldwork in India in 2008 consisting of 45 semi-structured 
interviews (with public health experts, policymakers, scientists, scholars, physicians, medical staff, private 
practitioners, consultants and members of the civil society and international donor community), visits to research 
institutes, patients’ homes and treatment sites. A first analysis of the data can be found in Engel (2008). 
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analyzes for example the design of TB programs, the translation of WHO policies into the 
national context of TB control pointing to the importance of power and processes of 
policymaking for TB policy design (Walt, 1999; Narayan, 1998; Porter & Ogden, 2001). Socio-
historical analysis of TB programs (Bannerjee, 1993; Chakraborty, 2003; Narayanan et al., 2003; 
Kathir 2006) offer insights into the role of (indigenous) research for policy and program design 
and the impact of the national public health system on policy implementation and TB control 
efforts.  
A perspective on innovation for TB control offers a more comprehensive reflection on change 
not only from a macro or policy perspective on the level of the TB program but at various levels 
(entrepreneurs, organizations, policy, program, system) and can take into account ongoing 
changes and improvements. With its central focus on both technological and social change it 
offers furthermore a reflection on progress in knowledge production and service delivery, on its 
drivers and barriers, on rigidities and flexibilities of the public health system in reacting to a 
changing or emerging public health challenge such as TB and the potential threat of MDR-TB. It 
can reveal how the system copes with uncertainty, how new opportunities are made use of 
(implementation, diffusion, discussion of appropriateness), whether there is a culture of 
innovation and how it looks like, whether and how social/technological change, improvements, 
new ideas are fostered, what barriers and drivers exist and what innovation and flexibility in a 
field level context mean. Thus, a framework for innovation in TB control should be the tool to 
provide answers to these questions. 
However, the case of TB in India also challenges existing literature on innovation which has 
mainly concentrated on the firm as the main actor, centered in recent years around innovation 
systems on a national, sectoral or technology level (Nelson, 2001; Edquist, 2001; Edquist, 1997; 
Malerba, 2004;, Carlsson, 1995; Jacobsson & Johnson, 2000) and has only started going beyond 
technological innovation, involving also change in services (Küpper, 2001; Tether & Metcalfe, 
2004) and organizations (sources Teece, 1998; Damanpour, 1991). The challenges and changes 
in TB control in India concern not exclusively new diagnostics, vaccines and therapeutics but 
also implementation, service delivery, access and adherence of patients, sustainability of the 
control efforts, and system related challenges. Although changes in technologies are clearly 
needed, they are strongly related to challenges and changes in service delivery. Thus, a 
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perspective on innovation is needed that goes beyond technological innovation, including aspects 
of services, delivery, system organization and institutions. 
In addition, TB is a public health challenge and thus mainly a public sector activity -although not 
exclusively: In India a vast, unregulated private medical sector caters to 70% of the population. 
Nonetheless, the state is the main actor responsible for TB control and therefore we are in need 
of concepts dealing with innovation in the public sector that are able to include activities in the 
private sector as well. An emerging strand of literature on healthcare innovation offers help 
(Cunningham, 2005; Consoli et al., 2006; Den Hertog, Groen & Weehuizen, 2005; Koch & 
Hauknes, 2005). These frameworks allow a broader understanding of innovation as change in 
knowledge production, service delivery, organizations, institutions and concepts and some of 
them have been developed particularly for the public sector. 
This paper will proceed with a short overview of some of the recent changes in TB control in 
India and in a second step examine existing frameworks on healthcare innovation along with 
recent developments in the innovation system literature upon their usefulness for an analysis of 
those cases. The aim of the paper is to find an initial conceptual framework to handle innovation 
in healthcare for the case of infectious diseases in developing countries, and more specifically 
TB in India which will be approached in the conclusion. 
 
 
2. Tuberculosis in India 
 
India is the country with the highest TB burden in the world. It has been estimated that there are 
1.8Mio. cases occurring annually. The huge death toll of the disease and the long-term impact on 
patients lead to a severe economic burden and human suffering. The links between poverty and 
TB are long established (Benatar, 2003; Farmer, 1997).  Potentially increasing numbers of co-
infection with HIV and the increasing emergence of strains that are resistant to anti-TB drugs 
might worsen the situation (Central TB Division, India, 2007).  
The Revised National Tuberculosis Program (RNTCP) is the TB control program of the Indian 
government and has at its core the DOTS strategy of the WHO4. Depending on the results of the 
                                                 
4
 The DOTS strategy is consisting of five elements: government commitment, case detection by sputum microscopy, 
standardised treatment regimens of 6-8 months with direct observation (DOT) for at least the initial two months, 
regular supply of anti-TB drugs, and a standardised recording and reporting system (WHO, 
http://www.who.int/tb/dots/en/ accessed on 20.7.2008). 
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diagnosis by sputum samples patients are distributed across four different categories5 and put on 
a strongly standardized treatment with several antibiotics. The drugs for the complete treatment 
are put in a box which is deposited at a DOTS provider in the patient’s vicinity (a local shop, 
pharmacy, post office or even a neighbour can be a designated DOTS provider). The patient has 
to swallow the drugs every alternate day under supervision of the DOTS provider. The 
government is in charge of the whole program from diagnosis centres to the delivery of drugs 
free of charge. 
Results from fieldwork confirm previous research done on TB showing that opinions about the 
success or failure and appropriateness of the DOTS program in India differ (Porter & Ogden, 
1999). Overall the RNTCP is judged by many as a success story particularly because of its 
internationally unprecedented rapid expansion in the recent years across the country. The 
RNTCP claims that it has achieved nearly full coverage across India (Central TB Division, 2007) 
but critical voices ask about the quality of that coverage since there is still a large number of 
patients who fail the treatment or who lack access to it (Interview with medical anthropologist, 
Pune, 29.1.2008; Chakraborty, 2003; Udwadia & Pinto, 2007).   
Confronted with this critique the government tends to argue that the biggest challenge in TB 
control is ensuring compliance of the patient to the TB treatment (Interview with medical officer, 
RNTCP, Government of Andhra Pradesh, 21.1.2008). The critics argue that the RNTCP is 
ignoring more social and cultural factors that could hinder a patient adhering to a treatment that 
comes practically to his/her doorstep (such as nutrition, transport, food security, other support 
mechanisms, gender or stigma). They argue that the RNTCP is purely based on the biomedical 
approach, on the battle against the germ, and that the human angle is missing (Interviews: health 
activist, Bangalore, 26.3.2008; medical anthropologist, Mumbai, 31.1.2008; professor in public 
health, Mumbai, 4.2.2008). These debates touch upon a classic public health dilemma between 
                                                 
5
 Depending on the results of three sputum samples the patient is put onto one of the three categories and 
subsequently on the standard DOTS treatment which takes 6 months  
- Category I: new smear positive patients, seriously ill patients, co-infected HIV patients 
- Category II: retreatment (defaulted and come back, failure and again started on treatment, relapsed cases (long ago, 
declared as cured, but again infected) 
- Category III: new smear negative cases, not seriously ill, extra pulmonary TB 
- Category IV: MDR, DOTS plus (not yet implemented) 
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biomedical values and socio-political values reflected in program design for TB (Porter & 
Ogden, 1999)6. 
The challenges that TB control in India is facing today originate from within the TB program7, 
the public health system8 and the wider social system9. Results from fieldwork show that the few 
suggestions that have been put forward in order to make the RNTCP more responsible to local 
contexts and needs as a result of operational research, mostly carried out by medical 
anthropologists, are difficult to include in the program; Partly due to politics, but also because 
they often involve huge commitment and resources from the program, the medical staff and their 
skills (Interview medical anthropologist, Hyderabad, 16.1.2008) which might not be 
operationally feasible10. According to public health decision makers often a balance has to be 
found between different solutions (Interview: former senior consultant World Bank, Delhi, 
05.03.2008).  
From the perspective of the government there is a clear trade-off between operational feasibility 
and individual, flexible care and implementation (that would respond to socio-political values). 
But the trade-off also holds for certain biomedical solutions that aren’t feasible to include 
because of financial or infrastructural constraints (f. ex. testing every patient for MDR-TB or 
                                                 
6
 Biomedical values characterize programs in standardized manner, assume that they are transferable between 
different contexts and evaluate programs in terms of cure and treatment rates. Socio-political values tend to see TB 
as a disease of poverty and demand from programs being flexible, accessible to patients’ needs and living 
conditions, dealing with the side effects of treatment regimes and other structural and social factors such as gender 
or stigma (Porter & Ogden, 1999). 
7
 There is a strong structure or protocol inherent in the treatment regime and one of the main points of critique from 
the private medical sector is that there is no room for care, for patient –practitioner interaction), flexibility in 
treatment, possibility to adapt to individual conditions or side effects, etc. (interview chest physician, Delhi, 
21.2.2008). The focus is entirely on cure as defined by the guidelines and completion of treatment according to a 
protocol. Care is reduced to cure by a box full of drugs. 
8
 The strong focus on population control and family planning during the 1980s and 90s and vertical infectious 
disease control programs have led to a slow deterioration of general public health services. Some of the most often 
cited challenges the public health system is facing today are poor surveillance and monitoring and therefore absence 
of reliable data, poor governance, corruption, lack of human resources and of stewardship, all of them strongly 
affecting TB control efforts (interviews: head national NGO, Hyderabad, 16.2.2008, health activist, Bangalore, 
26.3.2008; Interview with director Blue Peter Research Centre, Hyderabad, 10.3.2008; Bannerji, 1993). 
9
 Health is closely intertwined with economic development (Ramani & Mavalankar, 2005). Furthermore, it has been 
shown that issues such as nutrition, transport, food security, other support mechanisms, family or community 
support, gender or stigma influence access and adherence to treatment of TB patients (Rangan et al., 2003; Farmer, 
2001; interviews: health activist, Bangalore, 26.3.2008; chest physician, Delhi, 21.2.2008) 
10
 Furthermore, every change in the TB program involves a huge operational and resource intensive effort and it 
takes 3-5 years to roll it out in India given the size of the country (Interview with TB consultant, WHO India office, 
Delhi, 22.2.2008). Implementation of changes is not easy given constraints by the health system, lack of absorptive 
capacities, motivation, stewardship and the widely common political rivalry between state and centre government 
(Interview with microbiologist, research foundation, Mumbai, , 2.2.2008) 
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adding two drugs instead of one in the relapse treatment regime) (Interview with TB consultant, 
WHO India office, Delhi, 22.2.2008).11  
Thus, the fieldwork results show that even when the two positions in the debate of biomedical vs. 
socio-political values are acknowledged, the public health decision maker still has to undertake 
an almost impossible balancing act. There is a constant struggle between the social and the 
technical, between scientific knowledge, techno-managerial feasibility of the program and socio-
cultural factors. The struggle for this balance also characterizes the reactions to changing 
challenges such as MDR-TB and is important to keep in mind when looking at recent changes 
and debates in TB control in India.  
 
2.1 Recent changes and debates in TB control in India 
The results from fieldwork show that there is a dominant understanding from the government 
side that flexibility in reacting to a public health challenge might not be operationally feasible 
given the constraints of the Indian public health context whereas experts outside the TB program 
push for more flexibility and criticize the barriers to change (Engel, 2008; interview with public 
health consultant, international NGO, Hyderabad, 24.3.2008; chest physician, private hospital, 
Hyderabad, 12.3.2008; head of international NGO India office, 10.3.2008). 
Since implementation of the RNTCP started in 1997 several changes have been introduced to the 
TB program or are currently under discussion, some of them as a direct response to the threat of 
MDR-TB. In what follows, several of them are described in greater detail. 
 
2.1.1 Introduction of Public Private Mix 
In the last years the Indian TB policy has been shifting towards more substantial inclusion of the 
private sector and NGOs into the program in order to strengthen existing control efforts. The 
policy implies that NGOs can get registered as microscopy centres to diagnose TB or as DOTS 
                                                 
11
 These trade-off arguments that somehow hamper change are criticized by the philosopher of technology, Andrew 
Feenberg (2002, 1999), as misleading. Ethical controversies often get caught up in the opposition of current 
standards, but this opposition if factitious. Current technical standards and methods were once discussed and 
formulated as values, translated into technical codes and then taken for granted. The division between what appears 
as condition of technical efficiency and what as a value external to technical process is a process involving politics 
and biased by power. Farmer (2005) makes a similar argument related to the apparent trade-off between efficiency 
and equity in public health: an inegalitarian system can only be considered efficacious when unnecessary sickness 
and premature death dont matter. Regardless of these trade-off arguments being adequate or not, we found them to 
be prevalent in the thinking of decision makers in TB control in India. 
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providers. Furthermore, private physicians can now refer TB patients to microscopy centres and 
become DOTS providers (Interview: medical officer, RNTCP, Government of Andhra Pradesh, 
Hyderabad, 21.1.2008). In this way they keep their patients, can charge for consultations, but the 
patient receives the drugs free of charge. The idea gained strength in a private hospital in 
Hyderabad, where a well-known and highly respected chest physician was running a pilot project 
on involvement of private practitioners since 1995 funded by DFID and the WHO. Initially the 
government of India opposed the involvement of private practitioners and giving out the drugs to 
them. After the pilot project in Hyderabad had attracted interest of the WHO and was followed 
by many more pilot sites across the globe and several operational research studies had shown its 
importance (among others the work of a group of medical anthropologists has been influential in 
India), WHO Geneva developed a policy in 2001 for involvement of private practitioners in 
DOTS and subsequently the government of India included it in its RNTCP (Interview chest 
physician, private Hospital, Hyderabad, 12.3.2008). 
This is a good example of the initial resistance of the RNTCP against new ideas from the field 
and the strong influence of the WHO. In addition it shows the importance of individual 
entrepreneurs with personal relationships into higher bureaucratic levels. 
 
2.1.2 Sputum Collection Centres & improved sputum transport 
Another example of change in TB control comes from a NGO in Hyderabad which developed 
several so-called “TB models” to improve program implementation. They created the concept of 
sputum collection centres to overcome accessibility barriers (in rural areas these are geographical 
barriers in urban areas these are operational barriers as for example opening hours of microscopy 
centres) and improved the transportation of sputum samples by adding another chemical to make 
the sample transportable for a greater length of time (Interview with head of national NGO, 
Hyderabad, 16.2.2008). These innovations in implementation have been taken up by the 
government (again supported by personal relations) and are in the process of being implemented.  
 
2.1.3 Reacting to MDR-TB: new diagnostic tests & DOTSplus 
The improvement of diagnostic tests is seen by many researchers as one of the greatest 
challenges at the moment in TB control and in reaction to MDR-TB. The difficulty is to be able 
to distinguish between infection and active disease and to develop tests that are able to be 
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utilized in the current health system and its levels of absorptive capacity. (In endemic settings 
like India almost the entire population is infected with the mycobacterium TB but only around 
10% will develop the disease during their lifetime.) (Central TB Division, 2007; Interview with 
senior microbiologist, Tuberculosis Research Center (TRC), Chennai, 13.3.2008). As of now, 
there is absolutely no surveillance or diagnostic system for MDR-TB in the Indian public health 
system (Interview with microbiologist, research foundation, Mumbai, 2.2.2008). Diagnosing 
MDR-TB however, is not that simple. There are several techniques available or in development, 
but none of them standardized or evaluated for the TB program yet and all of them require higher 
laboratory capacity and bio-safety levels than currently in place (Interview with TB consultant, 
WHO India office, Delhi, 22.2.2008). Opinions differ about the appropriateness of different 
diagnostic techniques (solid culture, liquid culture, molecular tests) depending on turndown time, 
cost-effectiveness, feasibility, required laboratory and absorptive capacity of the public health 
system, etc. The strong focus on quality assurance for culture sensitive laboratories12 by the 
government (pushed by the WHO as many argue) is contested among public health experts and 
accused of slowing down the reaction unnecessarily since it is hampered by challenges inherent 
to the health system (mainly staffing) which might take a long time to change (Interviews: public 
health consultant, international NGO, Hyderabad, 24.3.2008; head of a national NGO, 
Hyderabad, 16.2.2008). These actors argue that fast reactions would be essential in dealing with 
the MDR threat and that it has to be seen how practical MDR diagnosis and treatment can be 
expanded and then simultaneously quality can be improved. 
Various research initiatives by public, private or NGO laboratories are looking into better tests or 
adapting existing ones for the Indian context. Among them the ongoing adaptation of a low cost 
diagnostic test from Peru to the Indian context by PATH in Hyderabad (an international NGO 
with a specific focus on health technologies), the development of a rapid diagnostic test by NGO 
research institutes such as the Foundation for Medical Research in Mumbai, the Blue Peter 
Research Centre in Hyderabad or the private Hinduja Hospital in Mumbai, and the joint effort of 
the WHO India, Tuberculosis Research Centre Chennai and FIND (an international NGO) in 
setting up a network of research laboratories across the country to evaluate diagnostic tests are 
interesting examples of efforts in technological innovations. 
                                                 
12
 For diagnosing MDR-TB laboratories are needed which are able to run culture sensitivity tests, e.g. testing the 
sensitivity of the TB bacteria to the most common anti-TB drugs. 
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In general, the treatment of MDR-TB is complicated, long, toxic, frustrating for the patient. Thus 
it cannot easily be standardized because it needs a lot of counselling and room for individual care 
which is difficult to include in a conform treatment scheme across India (Interview with chest 
physician, Delhi, 21.2.2008). The government is piloting treatment in accordance with the 
DOTSplus guidelines by WHO13 in a hospital in Ahmedabad in order to standardize the 
treatment scheme for MDR-TB.  
Debates revolve around how to best ensure adherence to MDR-TB treatment (Interview public 
health consultant, national NGO, Hyderabad, 16.2.2008)), and how to prevent spread of drug 
resistant strains14. 
The development of a new treatment regime can be characterized as a programmatic or 
healthcare delivery innovation. In accordance with these changes MDR-TB offers an opportunity 
to reintroduce flexibility into the control system.  
 
2.1.4 Changes on international policy level: new actors & the New Stop TB Strategy  
Further room for potential novelty is created by the existence of new funding opportunities 
(mainly the Global Fund to fight AIDS, Tuberculosis & Malaria). One of the most visible 
reactions to GFATM in India was the formation of a national TB consortium consisting of the 
largest Indian NGOs in the field of TB trying to become a primary recipient of the donor 
money15. Currently, there is room for change because of shared pressure from WHO and Stop 
                                                 
13
 MDR treatment according to the DOTSplus guidelines takes 24 to 27 months and involves injection and drugs 
intake at six days a week (and on Sunday drugs only) in the intensive phase of which some is spent at a hospital. 
Later the patients move to ambulatory phase and tablets only (depending on the weight, above or less 45kg these are 
10 or 13 drugs a day which are more toxic including worse side effects than the standard cocktail of antibiotics in 
the DOTS regimen.) The drug regimen DOTSplus is taken on a daily bases whereas in DOTS it is an intermittent 
regime. One can imagine that the existing problems of compliance are even bigger especially given the fact that 
most of the MDR patients already passed months or even years of unsuccessful TB treatment. 
14
 A person who is put on DOTS treatment can transmit the disease as long as he/she is sputum positive. The MDR-
TB patient put on a regular DOTS treatment will continue to be sputum positive, maybe less during some time. 
There will be a fall and rise phenomenon in the bacilli load. First maybe 20% of the bacilli will stay infectious, then 
these resistant ones rise to 40%. The initial improvement is then followed by worsening. Then the patient is sputum 
positive again and then she/he is transmitting only resistant organisms because the sensitive ones have died 
(Interview with chest physician, Delhi, 21.2.2008). 
15
 But the mechanism of the GFATM is such that the government is controlling the country level mechanism (CCM) 
and thus India’s application for support for TB control by the GFATM. This years’ call is asking for support from 
the civil society but the government is not applying for any financial funds from the GFATM. This is judged by 
many NGOs in the national TB consortium as a very arrogant move (Interview with public health consultant, PATH 
India, Hyderabad, 24.3.2008). There seems to be a lot of political ego and rivalry involved 
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TB partnership and regained international attention (Interview with microbiologist, medical 
research foundation, Mumbai 2.2.2008).  
In 2002 the WHO published the expanded DOTS framework which emphasized a need for more 
flexibility in TB programmes in order to be better prepared for changing challenges: 
“It is now necessary to widen the scope of the DOTS control strategy and make it a 
comprehensive support strategy – support to all providers, patients, and people to tackle 
the problem of TB. The expanded strategy lays equal emphasis on technical, managerial, 
social and political dimensions of DOTS. It acknowledges access to TB care as a human 
right and recognizes TB control as a social good with large benefits to society. It 
underscores the contribution TB control makes to poverty alleviation by reducing the 
great socio-economic burden that the disease inflicts on the poor.“ (WHO, 2002). 
 
According to Porter and Kielmann (2003) this implies a perspective on TB that goes beyond the 
objective and rational view of biomedicine. Even more so does the new six-point Stop TB 
Strategy that was initiated in 2006 (Stop TB Department, 2006) which is trying to address the 
challenges of DOTS in providing access to TB treatment and care, including TB/HIV and MDR-
TB patients. In addition, the new strategy seeks to strengthen health systems, engage all care 
providers, empower people with TB and communities, and promote operational and biomedical 
research16. International actors like the WHO and the World Bank had traditionally a very strong 
influence on TB policy in India (Walt 1999; Ogden et al., 2003). The adoption of these new 
global policy strategies is likely to trigger changes in more conceptual aspects of TB control. 
How far it actually impacts on national TB control efforts in India needs further examination. 
 
The above mentioned changes in TB control can be summarized as follows: 
 
Public Private Mix – changing healthcare delivery & involving new actors 
Sputum Collection Centre – changing healthcare delivery & access 
                                                 
16
 The new Stop TB Strategy is based on several approaches that have been explored by WHO globally since the 
introduction of DOTS: collaborative activities between HIV/AIDS and TB programs, effective ways of undertaking 
community care, and activities to engage all health care providers and strengthen primary respiratory care have been 
worked out; revised treatment guidelines and guidelines for treatment of MDR-TB (DOTS plus), international 
standards of TB care, and innovative mechanisms, such as the Global Drug Facility and the Green Light Committee, 
have been established to improve access to quality drugs,  and TB care is now viewed as a basic human right 
(reinforced by the recently drafted Patients’ Charter for Tuberculosis Care) Next to renewed international attention, 
new actors and alliances for development of new tools are beginning to produce results (Raviglione & Uplekar, 
2006; Stop TB Department, 2006). 
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Sputum transport – changing service technology 
New diagnostic tools – developing a new technique or technology  
DOTS plus – designing a new treatment scheme 
International policy level – changing international policy strategies and attention 
 
These instances of change reflect an understanding of innovation for infectious diseases that goes 
beyond scientific and technological novelty involving service and delivery aspects, changes in 
system interaction and conceptual understandings. This corresponds to an emerging strand of 
literature on healthcare innovation (Cunningham, 2005; Consoli et al., 2006; Den Hertog, Groen 
& Weehuizen, 2005; Koch & Hauknes, 2005) which has provided useful insights into the 
processes of innovation in healthcare albeit focused entirely on healthcare systems in Europe. It 
will be helpful to test and further develop these concepts for an Indian context. 
The next section will thus review this literature on healthcare innovation along with some recent 
developments within the literature on innovation systems, examining the particularities of public 
sector innovation, a potential definition for healthcare innovation, and the understanding of 
policy innovation and innovation system in order to develop a suitable framework to analyze 
innovation for TB in India. 
 
 
3. Towards a framework of healthcare innovation 
 
How to define innovation for TB control? We have seen in the preceding sections that TB 
control involves a variety of challenges among which the development of new drugs and 
diagnostics is but one factor. Thus, it needs a rather broad understanding of innovation taking 
into account the service and public sector characteristics of diverse improvements in TB control. 
The existing studies on healthcare innovation are related to innovation in the public sector and 
services. They are still very few and entirely based on a developed country context 
(Cunningham, 2005; Den Hertog, Groen & Weehuizen, 2005; Consoli et al., 2005). Nonetheless, 
they provide some important insights with regard to conceptualization and analysis of healthcare 
innovation. The following paragraphs will examine them along important elements that a 
framework to examine innovation for TB would need to cover, such as public sector and service 
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aspects, definition and characterization of innovation processes, handling of policy and system 
aspects, and analytical feasibility. It will be examined how useful existing concepts are for an 
application to TB control in India. However, the aim is not to give an exhaustive review of the 
innovation system literature but to draw upon selected insights of direct relevance to the case. 
This will provide the basis for the development of a theoretical framework to analyze innovation 
for TB control in India which will be approached in the last section. 
 
3.1 Healthcare Innovation – a Public Sector & Service Activity 
Health sectors are very complex and next to technological and organizational innovation, 
innovation in the public sector and in services is important (Den Hertog, Groen and Weehuizen, 
2005).   
Since TB control is a public health challenge it is important to consider that innovation in the 
public sector is understood to be qualitatively different from innovation in the private sector 
(Cunningham, 2005; Koch & Hauknes, 2005, Bhatta, 2003). It has been argued that innovation 
in the public sector is more than simple adaptation of innovations (product or processes, 
technologies or management procedures for example) developed in the private sector. It is 
characterized by non-market and non-private activities, it can include development of new 
products but more often it is application of existing products or processes, changes in service 
delivery, policy or organizations. Thus, it is related to the attempt to define innovation in service 
activities and implies a broader perspective on innovation than technological products and 
processes. 
However, according to Mulgan and Albury (2003) innovation in the public sector is often seen as 
an additional burden and not a core activity of vital importance as it is in the private sector. Thus, 
one needs to spend more time arguing why innovation in the public sector is actually important; 
an insight that is also reflected by the struggles of actors lobbying for innovation for TB control 
in the government of India (Interviews: public health consultant, international NGO, Hyderabad, 
24.3.2008; chest physician, private hospital, Hyderabad, 12.3.2008; head of international NGO 
India office, 10.3.2008). But since public sectors touch interests of so many and take over 
socially relevant tasks, innovations can meet new needs and old needs more effectively and thus 
resulting values can be very high (Donahue, 2005). Thus, innovation in public sector is 
happening in a different context due to the legislative power of the state, due to the public good 
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character and thus legitimacy and due to ethical dilemmas involved in the tensions between 
individual freedom, human rights and benefit of the masses.  
In the last 20 years it was realized how important it is for the public sector to innovate in order to 
adequately respond to changing environment and societies and growing expectations by citizens 
and private sector. But incentives to innovate for government organizations and employers have 
still been low (Mulgan and Albury, 2003). 
 
Among experts from the health sector innovation is mainly understood as a process leading to 
improved health system organization, improved quality or access, health management or security 
and surveillance or improved health care products. Often health policies treat science, technology 
and innovation as an exogenous variable17. Thus, in order to define innovative capacity for the 
healthcare sector an understanding is needed that goes beyond technological capacity including 
other elements such as social aspects of healthcare, new and effective means, managerial 
systems, processes of delivery, social and institutional mechanisms to encourage outreach, etc 
(Bhojwani, 2005)18.  
There is a strong need for insights into drivers and barriers of innovation, diffusion and 
implementation of new techniques, processes and systems in healthcare. The need for insights 
                                                 
17
 According to Ingeborg Meijer (Technopolis, NL, personal conversation 2007) health policymakers don’t really 
aim at getting involved with the innovation cycle. They rather wait what new products and processes come out of 
research and see whether they can use them. This happens according to Meijer mainly because public health as a 
public sector is trying to keep health costs low. New products mean in most of the cases more expenses in health 
care that have to be reimbursed. So why improve on products that already work? This is also the reason why health 
policy is mainly concerned with innovation in implementation and not the knowledge creation part which is often 
regarded as exogenous or not that important. However, the recent advances in biotechnology are offering so many 
opportunities which are almost uncontrollable that according to Meijer (2007) the technology is pushing health 
related innovation policy. In the case of TB in a country like India new products might be non-existent or too costly 
or resource intensive and thus operationally not feasible. In the case of rapid diagnostic tests where new solutions to 
diagnose MDR-TB are urgently needed the push comes mainly from requirements of the field.  
18
 The efforts of health sector reforms seem to be closely associated to these realizations. In general, health sector 
reforms are actions aiming at the improvement of the health system performance (Weil, 2000). It involves defining 
priorities, refining policies and reforming the institutions that implement the respective policies (Cassells, 1997). 
Very often it is reduced to processes of decentralization and introduction of user fees or privatization (Haddad et al., 
2008). In developing countries, the influence of the World Bank with regard to health sector reforms has been 
essential and not without criticism (Rao & Nayar, 2006). It is important to consider the context of health sector 
reform strategies and their potential implications for changing TB control efforts. However, health sector reform is 
but one factor contributing to the dynamic environment in which every infectious disease control effort today has to 
work. The understanding of healthcare innovation goes beyond health sector reform which is mainly concerned with 
improvements on the health system level and a very specific set of strategies whereas healthcare innovation will be 
used here in a more problem-oriented and much more open way, involving various changes in healthcare not only 
the ones related to decentralization, privatization, etc. Concrete health sector reform strategies however might 
overlap with or get translated into specific forms of innovation for TB. 
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into these innovation processes is placed within the somewhat under-researched area of service 
innovation (Den Hertog, Groen and Weehuizen, 2005).  
But the process of healthcare is not simply a delivery system. There is an important difference to 
industrial service development: Changes in the delivery constitute changes in the content of care. 
The way of implementing always affects the content of care provided (Den Hertog, Groen and 
Weehuizen, 2005). The content of care changes for the patient for example if the TB treatment is 
provided by a designated DOTS provider in his/her vicinity and not by a physician at a TB 
hospital. This is why it is so essential to look at changes in delivery and services and 
implementation.  
However, innovation in healthcare is not limited to innovation in implementation or delivery. 
There are strong linkages between the production of knowledge and access to and quality of 
health care. The content of care also changes with progress in knowledge and the context of care 
might influence production of knowledge. In India this can be exemplified by ongoing 
developments of liquid culture tests for diagnosing MDR-TB that require lower laboratory 
capacities than molecular tests despite the method is somewhat outdated. 
It has been argued that product innovations like drugs, diagnostics and vaccines are needed but 
that the invention is built on the firm ground of scientific evidence and it is more a question of 
whether this evidence gets used and applied (Den Hertog, Groen and Weehuizen, 2005). From a 
social constructivist point of view this is too much in line with a technology-push perspective. 
Especially with regard to developing countries this implies a simple technology transfer model 
which is not adequate given the range of other factors influencing development and uptake of 
technology and also appropriateness of technological solutions or interventions. However, it 
reflects to some extent the thinking that seems to be inherent in the current understanding by the 
WHO and the Central TB Division in India of TB as being mainly an implementation challenge 
(Interview medical officer, RNTCP, Government of Andhra Pradesh, 21.1.2008) and it is also 
inherent in the DOTS strategy itself. The narrow focus on implementation and patients having to 
swallow the drugs is one of the main points of critique on the RNTCP by public health experts 
outside the government (see chapter 2). It furthermore illustrates the strong dependence on 
biomedical knowledge and the scientific driven nature of healthcare solutions. 
To conclude, changes in knowledge production and service delivery are interwoven and highly 
interrelated in healthcare. However, service innovation or operational innovation, innovation in 
 20 
institution, delivery and policy is important and rather complex in health care systems and there 
are important differences to industrial service delivery (Den Hertog, Groen and Weehuizen, 
2005). A conceptualization of innovation should thus incorporate these diverse forms of 
innovation and the emphasis on delivery and services. 
 
3.2 Defining Innovation in Healthcare 
The emerging work on public sector innovation understands innovation as a research heuristic, as 
an analytical tool not a descriptor of an objective reality (Koch & Hauknes, 2005). Based on the 
insights of the above discussion the following conceptualization for innovation in healthcare of 
Cunningham (2005) will be used as a working definition for innovation in TB control in India: 
Innovation in healthcare is understood as “…doing something new i.e. introducing a new 
practice or process, creating a new product (good or service), or adopting a new pattern of intra- 
or inter-organisational relationships (including the delivery of goods and services)” 
(Cunningham, 2005). The emphasis is on novelty but not every change equals innovation only if 
there is new knowledge introduced as for example the recruitment of workers in order to import 
new knowledge or carry out novel tasks. According to Cunningham (2005) an innovation can 
contain some or all of the following elements of novelty/change: 
 New characteristics or design of service products and production processes 
(Technological element) 
 New or altered ways of delivering services or interacting with clients or solving tasks 
(Delivery element) 
 New or altered ways in organising or administrating activities within supplier 
organisations (Organisational element) 
 New or improved ways of interacting with other organisations and knowledge bases 
(System interaction element) 
 New world views, rationalities and missions and strategies (Conceptual element) 
 
The change that qualifies for an innovation can thus happen along some or all of these elements. 
This differentiation seems to be very useful to analyze different forms of innovation affecting TB 
control in India. All of these elements have been or are currently subject to change some of 
which have been discussed above. According to this understanding we can characterize the 
examples discussed in chapter 2 as follows: 
 
Public Private Mix - delivery & organizational & system interaction & conceptual element 
 21 
Sputum Collection Centre - delivery & organizational element 
Sputum transport - technological & delivery element 
New diagnostic tools - technological & system interaction & conceptual element 
DOTS plus - technological & delivery element 
International policy level - conceptual element 
 
Furthermore, the innovation environment (the health sector, social system) is important where 
competing or facilitating developments happen and organizational capabilities and socio-
technical constituencies influence the innovation (Cunningham, 2005). 
We have shown elsewhere (2008) that it is argued by the government of India that operational 
feasibility which is strongly related to the weak public health system and the size of the country 
is often a factor impeding change and innovation. There are strong links between poverty, the 
status of the health system (Hammer et al., 2007, Ramani & Mavalankar, 2005) and broader 
social system challenges (f.ex. migration, urbanization, privatization) and the persistence of TB 
and the emergence of MDR-TB (Farmer, 1997; Singh et al., 2002). TB is still a poverty related 
disease although the disease is showing up in wealthier parts of the society as well (Interview 
health activist, Bangalore, 26.3.2008).  
 
It is discussed that the big paradox in health care innovation seems to be that the functioning of 
the health care system cannot keep up with progress in technological and professional 
competencies and is not able to profit from it (Hertog, Groen, Weehuizen, 2005). This contrast 
might be even bigger in a country like India, where the health system is facing additional 
structural problems and might be even less able to adopt and make use of existing knowledge or 
new technological opportunities. 
It is thus important to examine how socio-political, socio-economic processes and cultural 
factors such as the current status of the health system, poverty, caste, education, stigma or gender 
impact on what forms of innovations are produced and thought over. As a health activist we 
interviewed argues: Any disease control effort should also aim at social innovation and 
sensitization of the health system (Interview Bangalore, 26.3.2008; Narayan & Narayan, 1999) 
towards these social aspects. Currently there seem to be changes happening within the Indian 
health system (f.ex. stronger integrated primary health services, development of capacity and 
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skills through Public Health Foundation) which might help to foster innovation and make the 
system more receptive to change. But these developments are only in their initial phases, are 
contested in their usefulness (Rao & Nayar, 2006), and it will take some time until they show 
any impact. The question is whether the current pace of change is sufficient to meet emerging 
requirements from the field such as growing MDR-TB and HIV co-infection. 
Health systems are a complex set of rules, social norms, cultural values and policies, informal 
practices and tensions over professional boundaries and activities of actors and employers. Since 
most of these factors are institutionally rooted the respective improvements or solutions towards 
sustainability require systemic innovations or system transformations (Grin & Rotmans, 2005). 
Resistance to change has been observed widely and initiation of change is thus complicated 
(Callon, 1995; Elzen et al., 1996; Rip & Kemp, 1998). The literature on system transformation 
deals with these more systemic innovations (Grin & Rotmans, 2005) and offers instruments how 
to encourage or speed up such transformations (such as social experiments and strategic niche 
management) (Geels, 2002; Kemp, 2006).  
There is definitely a need for a transition towards sustainability in the Indian health system and 
also in TB control for which several of our interviewees have argued (Interview health activist, 
Bangalore, 26.3.2008). There has been a change for example in vision and understanding in the 
way the WHO is dealing with TB. But whether this is reflected in more integrated and holistic 
actions in India needs further research. 
However, one has to be aware that the discussion around future health system development is 
framed and conceived mainly based on experiences in a few advanced market economies with 
specific historical developments. This perspective might therefore not be optimal for low and 
middle income countries where it is very difficult to develop widely accepted health strategies 
and institutions given the dynamic context, the fragmented societies and multiple framings of 
sustainability (Bloom et al, 2007; Bloom & Standing, 2008). 
The analysis should include these more systematic aspects of change and the embeddedness of 
the healthcare innovation within broader social systems and their impact on changing TB control 
efforts. In what follows, such integration is proposed. 
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3.3 The Need for a Problem-Orientation and Transient Systemic View 
The literature on innovation has emphasized jointly the systemic character of innovation 
processes and teaches us the importance of connections and linkages among actors of the system 
in order to foster learning (Mugabe, 2005; Nelson 2001; Malerba, 2004; Edquist, 1997).  
But how to make sense of the diversity of the different innovation processes that have been 
mentioned above? Most of the innovation literature focuses in case studies on a particular case of 
innovation or on an innovation system with national, sectoral or technological boundaries (f.ex. 
Nelson, 2001; Malerba, 2004; Jacobsson & Johnson, 2000)19.  
 
Our aim is to take a holistic view on progress in TB control that goes beyond a retrospective 
focus on single cases of innovation but examines barriers and drivers of changing and emerging 
practices along a particular public health challenge. We are interested in showing TB as a public 
health challenge in changing contexts and conditions with a variety of innovations that are 
fostered and implemented in response to those changes. Therefore a problem-oriented 
perspective on ongoing change processes is needed. 
By putting the focus on an entire disease, thus embarking on a problem-oriented perspective on 
TB itself, we can examine different problem definitions and understandings, the development of 
the definition of the object of progress and changes in the dominant system of thought. Consoli 
et al. (2005) analyzed the history of medicine for a particular problem and were able to show that 
it is defined by struggles over definition of what the problem is and therefore progress is also 
defined differently along with these different understandings.  
In the same line Tether and Metcalfe (2004) argue that in order to be able to analyze the diversity 
involved in service innovation it helps to have a very transient and dynamic understanding of 
innovation systems where boundaries and actors are not fixed but evolve as the problem or the 
opportunity changes or is redefined20. This supports a perspective on change in practices along a 
                                                 
19
 If the innovation system concept is applied to a developing country context the definition of innovation (which 
can be also imitative innovation, innovation as a learning process) and external pressures due to globalization on the 
national innovation system are important (Metcalfe & Ramlogan, 2006; Mytelka, 2000). If one focuses on 
innovation in the public sector in a developing country issues such as external pressures from international donor or 
NGO communities are becoming important as well. Systematic weaknesses of the innovation system related to weak 
political-policy processes and institutions (Mytelka & Oyeyinka, 2003) are additional problems in developing 
countries. 
20
 According to Tether and Metcalfe (2004) the understanding of innovation in services within the innovation system 
literature does not reflect the actual diversity of innovation in services which is characterized by interrelationships 
between business models, organizational forms, technology and outputs which form important components and 
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particular problem such as TB control. When we understand innovation systems as evolving 
around problem sequences and opportunities, as constructed and equipped with a certain purpose 
(Ramlogan & Metcalfe, 2006; Mina et al., 2003), the innovation system concept loses its static 
boundaries (national or sectoral), allows analysis of frames of understanding and power and 
becomes more suitable to reflect on direction and guidance of innovation towards socially 
desirable goals or public goods such as public health. 
 
Support for this argument comes from a recent development in innovation system literature 
which understands the concept of innovation systems more as a heuristic attempt to analyze 
actors, institutions and networks contributing to innovation (Hekkert et al., 2007). These authors 
argue that most of the innovation system analysis focus on the description of the structure of an 
innovation system on a macro level neglecting individual entrepreneurs and are thus too static 
and not able to provide insights into the actual dynamics within innovation systems. They argue 
for the need to understand how innovation systems function21, for a systematical mapping of the 
activities that foster or hamper innovation (Hekkert et al., 2007).  
Furthermore, the importance of the local level in addressing issues of innovation has been 
acknowledged in a recent workshop held on the contribution of innovation to reduce poverty, 
hunger and disease. It was argued that cultural drivers and barriers to innovation have to be 
examined in-depth, and it has to be kept in mind that an aversion towards risk and resistance to 
innovation might not be per se 'irrational' (INNO GRIPS, 2007). 
This corresponds with research in healthcare innovation processes and is precisely what our 
research on innovation dynamics around TB control is aiming to do, albeit not only focused on a 
technology as Hekkert et al. (2007) propose. 
 
Several of our interviewees argued that the response to TB is always a reflection of the current 
status of the health system and wider social systems (Interviews: professor in public health, 
Delhi, 25.2.2008; medical anthropologist, Mumbai, 31.1.2008; health activist, Bangalore, 
                                                                                                                                                             
therefore knowledge other than R&D or technological knowledge such as market and procedural knowledge is 
important. The diversity of innovations in services and the multiple interactions between the system components and 
actors implies that there are several innovation systems forming and evolving along problem sequences. 
21
 Hekkert et al. (2007) proposed functions of innovation systems as the processes that are highly important for well 
performing innovation systems. 
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26.3.2008) and thus it is important to take these contexts into account. TB control in India has a 
long history both in terms of control efforts and policy development which often reflected socio-
political conditions of that time (Bannerjee, 1993; Narayanan et al, 2003). According to a health 
activist (Interview Bangalore, 26.3.2008) the focus on technology and technological innovation, 
including program innovation is one way of addressing a problem like TB. The solution might 
look different if TB would be widely believed as a crippling problem, a humanitarian crisis. A 
similar argument has been made in the sociological history literature on social construction 
(Callon, 1999; Hughes, 1999). Thus, the definition of the problem constitutes the innovation 
system, it guides the kind of institution or policies that are set up, the search for solution and the 
effort put into it.  
Existing public health debates show the tensions between biomedical and societal values (Porter 
& Ogden, 1999; Walt, 1999) and thus the importance of analyzing innovation for TB control in 
its context and with its politics.  
A problem-oriented perspective allows examining the context and understandings which are 
leading to specific changes. In addition, it allows an analysis of innovation practices that are still 
ongoing or in initial phases such as the reactions to the emerging threat of MDR-TB. 
 
Consoli et al. (2005) developed a scheme of progress in medical practice that applies such a 
problem-oriented perspective according to which the progress of medical practice can be 
characterized along four broad issues: 
1. Epistemic: evolution of medical and scientific knowledge embodied in technology and 
procedures for diagnosis and therapy 
2. Organizational: different ways the medical innovation system is resourced, constructed 
and organized 
3. Institutional: informal and formal regulation of medical innovation and diffusion 
4. Cultural: different understandings of the medical problem in different communities 
Consoli et al. (2005) focused on the key scientific and technical advancements which 
characterized the history of medicine for a specific disease and highlighted the linkages between 
understanding, diagnosis and therapy, showing the dynamics between advancements in science 
and the techniques in place. However, the framework aims to explain production of knowledge 
not taking into account the service aspect of healthcare delivery. As has been argued above the 
aspect of delivery of care is essential for TB control in India. 
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The dimensions of the framework are very similar to Cunningham (2005) with a focus on 
organization, institutional/systemic and conceptual/cultural factors. However the framework of 
Cunningham is more suited to analyze change in services because it differentiates between 
change in technology and delivery elements. But it lacks the focus on how a problem is defined 
and understood by different actors, how this understanding develops over time and impacts on 
the innovation processes. For an analysis of TB control in India one could therefore use the 
framework of Cunningham (2005) and embody the idea of Consoli et al. (2005) to look at 
evolution of progress along the different elements or dimensions; thus allowing a more problem-
oriented perspective. 
 
 
3.4 Fostering Healthcare Innovation: Policy Learning 
The main responsible actor in public health is the government. However, as results from 
fieldwork show the government is not necessarily the main actor fostering innovation and 
change. Cunningham (2005) found that innovation in public sector is complex, involving a range 
of different, interlinked innovations and actors and with potentially diverse, far-reaching impact, 
thus the process fostering such innovations will also be complex.  
Furthermore, Arentsen, Kemp and Luiten (2002) argue that although governments bear a special 
responsibility towards society in guiding future development, socio-technical change is a multi-
actor process, characterized by immense complexity and fuelled by millions of decisions of 
different actors, where government can not manage or control such change processes top-down. 
Rather, socio-technical change is a governance challenge (referring to decisions and actions of 
public and private actors) than just a challenge for governments’ policy (which is democratically 
legitimized collective decision-making and policy action). The government can thus develop 
policy strategies that are able to support, strengthen and redirect governance of many actors 
involved in socio-technical change processes in socially responsible directions (Arentsen, Kemp 
& Luiten, 2002). 
 
TB control in India is not a system that has at its core the aim to create innovations, new 
solutions and ideas, but the core aim is to implement an existing solution, to deliver a service and 
in this way cope with a problem (Engel, 2008). The government will very unlikely be the main 
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trigger of innovative efforts or practices. Rather they are imposed from outside, either by 
requirements from the field (emergence of new challenges), individual entrepreneurs or 
international actors such as the WHO. According to actors pushing for change in TB control in 
India it is essential to convince the government of taking up the innovation and integrate it into 
the RNTCP in order to have a meaningful impact (Interviews: public health consultant, 
international NGO, Hyderabad, 24.3.2008; chest physician, private hospital, Hyderabad, 
12.3.2008). 
Thus, there is no formal innovation policy for TB in India in a narrow sense but there has been 
policy innovation or policy learning affecting TB control22.  
This confirms the argument that has been made that policy learning or policy innovation is an 
important element of innovation in public sectors such as health and that innovation should be 
based upon and accompanied by policy learning (Kemp and Weehuizen, 2006; Cunningham, 
2005). According to Kemp and Weehuizen (2006) policy learning is a conscious and structured 
change in thinking about a specific policy issue and innovation is a change in doing. A change in 
practices can precede or be followed by a change in thinking. “Policy learning is often (and 
possibly always) a precursor of innovation in the public sector, and it is a possible (and 
desirable) consequence of innovations that have been adopted, and thus again a possible 
precursor for new innovation, in a cause-effect chain.” (Kemp & Weehuizen, 2006). 
Most of the innovations for TB mentioned in the previous paragraphs have been accompanied by 
policy learning or shift in policy. Given the high dependency on different forms of expert 
knowledge in the case of infectious disease policy it is believed to be useful in assessing policy 
learning and the knowledge based on which it is happening. 
 
Cunningham (2005) includes policy learning in his analysis of innovation drivers and barriers. 
The separation of an analysis of service delivery and policy issues within the cases was found to 
be artificial because processes of policy learning and innovation in healthcare are overlapping 
and interlinked, involving different innovation environments. In TB the policy and service level 
are strongly related as well since the government is not only responsible for policy formulation 
                                                 
22
 Innovation policy is understood as policy explicitly aimed at fostering innovation, whereas policy innovation is 
understood as change in policy or policy learning. Policy learning can be broadly defined as a change in the way of 
thinking (Kemp & Weehuizen, 2006) or as Koch & Hauknes (2005) put it the ability of the policymaker to learn 
what is needed in order to change behaviour.  
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but also service delivery of the program although the latter is done by the state governments who 
are rarely involved in policy formulation. 
Cunningham decided to combine policy and service delivery issues and focus on policy learning 
throughout the innovation analysis. The policy change is integrated into the assessment of the 
innovation process. It is recognized that policymakers play an important part as facilitators and 
drivers and their actions, reports and decisions thus receive due attention. But the policy learning 
is not explicitly analyzed in the same way as the literature on policy change suggests (by 
identifying actor coalitions, discourses etc) although elements of such an analysis can be noticed. 
It remains a bit unclear how exactly such an analysis can be undertaken. 
In general, the literature on public sector innovation acknowledges the importance of policy 
beliefs for framing problems and directing change (Kemp & Weehuizen, 2006). 
This points again to the importance of applying a problem-oriented view and understanding 
innovation and accompanying policy learning as evolving around the problem sequences or set 
of opportunities that are defined by the constituencies involved (Metcalfe and Ramlogan (2006), 
Mina et al, 2003; Consoli.et al., 2005). 
There is a vast literature in political science examining interests, institutions and discourses in 
shaping policymaking (Sabatier, 1991; Rein & Schön, 1993; Hall, 1993; Hajer, 1993; Grindle, 
1999; Kingdon, 2002). Kemp and Weehuizen (2006) argue that the literature on policy learning 
is very much concerned with the effects of learning and not so much with a detailed analysis of 
how people learn (for example through experience, observation, systematic study, interaction). 
They propose to simplify the analysis and link it more to innovation in public sector by looking 
at different types of policy learning (technical, conceptual and social learning, which would work 
with the framework of  Cunningham, 2005 & Consoli et al., 2005), at what has been learned, 
how it has been learned and what role this learning played for the policy change by conducting 
interviews and undertake document analysis.  
A recent overview of health policy analysis in low and middle income countries clearly shows 
how important it is to integrate politics, process, and power into such studies. The literature on 
policy change in low and middle income countries is still very fragmented, diverse and mainly 
descriptive (Gilson & Raphaely, 2008). For India only a handful of studies have examined the 
Indian health policymaking process (Mooij, 2003; Mooij, 2007; Jeffery, 1988; Porter & 
Kielmann, 2003, HEPVIC, 2006).  
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Thus, it is felt to be equally important to analyze discourse coalitions trying to influence policy 
making, thus incorporating more political aspects. However, such an analysis also depends on 
access and depth of material and data available. These complex processes are requiring long-
term and in-depth analysis which might be only possible from an ex-post perspective. However, 
some of the changes in TB control in India mentioned above are ongoing. A decision on how 
policy learning can best be integrated theoretically will have to be based on insights from further 
empirical research. 
 
To conclude, policy learning is a central element in healthcare innovation but the main driver for 
healthcare innovation is not necessarily the state. It is thus useful to analyze drivers and barriers 
of healthcare innovation where the state plays an important part in shaping or encouraging multi-
actor governance processes of change. The next chapter looks at how such an analysis can 
actually be undertaken. 
 
 
3.5 Analyzing Healthcare Innovation 
Studies on public sector innovation in the UK look at drivers and barriers for the initiation of a 
particular innovation and the factors influencing development, diffusion and acceptance of that 
innovation. They place this analysis within the wider context of institutions, services and 
national public health sector. "Thus, the characteristics of the individual innovations could be 
examined within their wider service and policy reference frames and specific policy lessons 
identified." (Koch & Hauknes, 2005). The innovation process is understood as an iterative, 
complex process. However, the authors argue that for an analysis it makes sense to use a life 
story, and thus rather linear, model of an innovation and map developments along it 
(Cunningham, 2005; Koch & Hauknes, 2005). 
It has been argued that there is still a common temptation in debates on medical innovation, 
particular innovative health technologies, to fall back on a linear model of innovation by 
emphasizing policies to facilitate the translation of basic research into clinically useful 
technologies and practice. But as Consoli et al. (2005) show this understanding is inadequate, the 
progress in medical know-how is much more based on multiple and multiple-directional 
relationships. "..there is a two way street between bedside and bench." (Consoli et al., 2005). A 
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qualitative, detailed analysis of drivers and barriers of the different innovation processes 
presented above would provide insights into actual innovation dynamics and be able to show the 
different multi-directional relationships in these processes.  
 
Cunningham (2005) examined in exploratory case studies drivers and barriers of different 
healthcare innovation cases in Europe (using an embedded case study approach, Yin, 1989) and 
focused on policy learning throughout the innovation analysis. The origins of the innovation in 
question and the critical events in its development were tracked. The context of the innovation 
was examined by mapping the national health system and the immediate innovation 
environment. Key actors, structure, processes and critical events for the actual innovation case 
were analyzed. They found that dialogue and openness to change among key groups are required 
and often missing. Furthermore openness to think outside the box, teamwork, independent 
thinking and seizing of opportunities and innovation champions are crucial. Other important 
drivers can be a new challenge from the field, political push, change in culture, competitive 
drivers (such as targets although they can also hinder innovation) and technological factors. 
Barriers can exist in the form of size and complexity of the health system, heritage, legacy, 
routines, professional resistance, risk aversion, political profile and accountability, complexity of 
public health decisions and potential impact, large range of stakeholders that need to be 
consulted, pace and scale of earlier change within the system, lack of capacity for organizational 
learning, lack of resources and technical barriers. 
The preliminary insights from field work found all of these barriers being prevalent in the TB 
environment in India. They have been cited by public health experts as important problems 
hindering the success of TB control and implementation of the TB control program and they 
have been characterized by critics of the program as rigidities inherent in the system hampering 
innovative responses to new challenges such as MDR-TB. Some of the drivers that have been 
identified so far are innovation champions, influence of international actors and requirements 
from the field (Engel, 2008). 
 
However, as we have argued in preceding chapters the focus on individual innovation cases 
should be replaced for this analysis by a problem-oriented view and thorough integration of 
different system levels. 
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Den Hertog, Groen & Weehuizen (2005) are mapping patterns of innovation through the 
healthcare system. They emphasize interaction and cooperation between different functions and 
disciplines within the healthcare process and between different system levels of actors like 
policymakers, practitioners and managers. In order to enhance interaction and therefore 
innovation the potential walls and ceilings have to be broken through. They argue for the 
importance of innovation coalitions and the multilevel character of healthcare innovations.  
In India we found tensions between political staff trained in administrative skills and technical 
staff, between private and public practitioners where professional autonomy is a source of 
resistance to change. In the same time innovators from bottom-up were found to be frustrated 
because they are unable to scale up and lack support and political commitment (interviews: 
public health consultant, international NGO, Hyderabad, 24.3.2008; chest physician, private 
hospital, Hyderabad, 12.3.2008). 
 
However, despite these hints it remains unclear how exactly successful improvements made their 
way through the Indian healthcare system, which innovation coalitions have been involved and 
what walls and ceilings had to be broken down. It seems useful to examine the above mentioned 
instances of change in TB control in more detail, analyzing drivers and barriers in order to test 
and further develop these concepts for a developing country context and the infectious disease 
area.  
 
 
4. Summing up: a conceptual framework for innovation in TB control 
 
After this short review of results form the field and corresponding theory we can conclude that 
the recent developments in innovation system literature such as embracing activities in services 
and public sectors, trying to understand micro-level innovation dynamics and linking it to system 
level transformations towards sustainability is helpful in providing insights for a framework to 
analyze change and innovation dynamics around public health challenges such as TB in India. 
 
As the initial insights into changes in TB control have shown there is a need for a broader 
understanding of innovation including aspects of delivery, services, organizations and systems 
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while taking into account the particularities of healthcare as a public good and public sector and 
the importance of the wider social system. A useful working definition has been presented in 
chapter 3.2 that takes these considerations into account. 
We have seen how important policy learning is for healthcare innovation which is also confirmed 
by results from the field of TB control pointing to the political nature of the case. However, the 
existing concepts on healthcare innovation are a bit unclear as to how exactly an analysis of 
policy learning can be included. Here seems to be room for theoretical contribution and further 
research.  
Furthermore, the link to existing innovation system concepts has been explored and it has been 
argued for an understanding of innovation systems as constructed, with a purpose, highly 
transient and dynamic and evolving around problem sequences (Mina et al, 2003; Ramlogan & 
Metcalfe, 2006). A fundamental question to an innovation system is according to Ramlogan and 
Metcalfe (2006) the openness of the current structure towards innovative challenges, an aspect 
which would be an important outcome of an analysis of innovation for TB control in India; 
particularly in the light of international policy calls for flexible reactions to emerging infectious 
diseases.  
 
The recent changes in TB control that have been introduced since the implementation of DOTS 
in India in 1997 and which have been characterized above as consisting of different elements of 
healthcare innovation need to be analyzed in greater detail. Such an analysis will map drivers and 
barriers along changes in technological, delivery, organizational, system interaction and 
conceptual elements, examine interaction and cooperation between different functions, 
disciplines and system levels within TB control.  
Given that the conditions are not necessarily fostering change, it will further be interesting to 
look at failed innovation attempts and local changes that weren’t taken up (yet) and introduced 
into the TB program. Thus, the analysis goes beyond an ex-post examination of introduced 
changes involving ongoing change efforts as well. The understanding of governance of 
innovation for TB control as a multi-actor process that can be influenced by the central and state 
governments, by health staff, researchers, patients or the disease itself will be helpful in this 
regard. 
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Such an analysis can reveal how a public health control structure copes with uncertainty created 
by changing challenges, how new opportunities are made use of, whether there is a culture of 
innovation and how it looks like, whether and how social/technological change, improvements, 
new ideas are fostered and what barriers and drivers are impacting these developments. The 
analysis is however not judgemental or evaluative although different opinions and positions are 
represented. Rather, it aims at showing the development of change and improvements within 
public health policy and control practices along a specific public health challenge. 
A further exploration of the above mentioned instances of innovation in TB control will provide 
insights into the meaning and usefulness of flexibility and innovation for a public health system 
in a country like India that is confronted with a changing challenge such as TB. These insights 
can help to explore what can be done in order to enhance and foster response capacity of a public 
health system and simultaneously contribute to theoretical literature on innovation in healthcare. 
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